CA 19–9, GICA (Gastrointestinal Cancer Antigen)

Lamerz, R.

doi:10.1007/978-1-4612-0401-5_14

Cited by 9 publications

(7 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our patients, a simple reflection of serum levels, however, is highly unlikely to account for the elevated levels detected in saliva because even in a 5‐year follow‐up, there was no occurrence of any malignant or nonmalignant disease known to lead to a CA 19‐9 elevation such as hepatobiliary disease or obstruction, a tumor of the contralateral parotid gland, or an undetected carcinoma ex pleomorphic adenoma in the resected tumor. On the other hand, according to the literature, CA 19‐9 may be detected in high levels in body fluids despite normal serum CA 19‐9 6 . It remains unclear why this seems to have been the case only in single cases in our study.…”

Section: Discussioncontrasting

confidence: 44%

Carbohydrate Antigen 19‐9 in Saliva

Dyckhoff

Warta

Gonnermann

et al. 2011

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 44%

Carbohydrate Antigen 19‐9 in Saliva

Dyckhoff

Warta

Gonnermann

et al. 2011

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“…The use of serologic tumor markers for pancreatic carcinoma, such as CA 19-9 has an important role in diagnosis and monitoring of patients with pancreatic malignancies. Serum elevations of CA 19-9 with highest incidence rates are reported for pancreatic carcinoma (1,20,32).…”

Section: Discussionmentioning

confidence: 99%

“…This marker is useful in following of disease and in assessing the adequacy of resection (20,21). CA 19-9 is thought to be the most reliable marker for the diagnosis of pancreatic cancer (6), and its prognostic value for the evaluation of patients with inoperable adenocarcinoma of the pancreas is important (21).…”

Section: Recognition Of Unusual Lesions and Differentiation Of Chronimentioning

confidence: 99%

Evaluation of imaging techniques and ca 19-9 in differential diagnosis of carcinoma and other focal lesions of pancreas

et al. 2004

View full text Add to dashboard Cite

BACKGROUND: Ultrasonography and magnetic resonance imaging are the most important imaging techniques in the diagnostics of pancreatic carcinoma and disease staging; they are also very useful in monitoring and follow-up of treatment efficacy. The problems with imaging diagnostics arise in certain cases of pancreatic focal lesions - for example in the differentiation of focal chronic pancreatitis and pancreatic carcinoma. Our objectives were the evaluation of ultrasonography and magnetic resonance imaging reliability and determination of the importance of tumor antigen CA 19-9 in the diagnostics of pancreatic carcinoma. METHODS: Our investigation included patients with pancreatic focal mass suspected of malignancy. All patients were examined by ultrasonography, MR, and ultrasound-guided needle biopsy. Cytopathologic examination of biopsied samples was used to diagnose the disease. Oncomarker levels CA 19-9 were assayed in all patients. RESULTS: Magnetic resonance imaging and ultrasonography examination made possible the correct diagnosis of carcinoma in case of 17 patients; in three patients with focal chronic pancreatitis the diagnosis was false positive. No case of false-negative diagnosis was found. The tumor antigen CA 19-9 in serum was determined and it was clearly positive (above 45U/ml) in all patients (17) with pancreatic cancer. CONCLUSION: Imaging techniques gave good results in the evaluation of pancreatic pathology. However, when using imaging techniques differential diagnosis between focal chronic pancreatitis and pancreatic carcinoma seems to be major problem. Correlation of imaging technique and determination of tumor antigen CA 19-9 has an important role in the diagnostics of pancreatic carcinoma. Imaging techniques and identification of tumor antigen CA 19-9 are complementary methods in the examination and diagnostics of pancreatic carcinoma and they allow better precision of diagnosis of pancreatic focal lesions

show abstract

“…[1,6,7] CA 19-9 is a hapten of the human Lewis antigen blood group determinant with a molecular weight of 36 kD. It is found in many mucosal cells and their secretions, [8,9] and it is used for differential diagnosis and follow-up in pancreatic cancer, [1,10] as well as in follow-up assessment in hepatobiliary cancer and stomach cancer. [11] Increased levels of CA 19-9 are also found in other malignant and benign diseases.…”

Section: Introductionmentioning

confidence: 99%

“…[11] Increased levels of CA 19-9 are also found in other malignant and benign diseases. [9] CA 125 is a high-molecular glycoprotein with a molecular weight of approximately 200 kD, referred to as mucin MUC16. [12] It is a regular component of the surface epithelium of the female genital tract.…”

Section: Introductionmentioning

confidence: 99%

Method Comparison for Ca 15-3, Ca 19-9, and Ca 125 Determination Using the New Loci Technique of Dimension Vista 1500 and Immulite 2000 Xpi

Zur¹,

Holdenrieder²,

Albers³

et al. 2012

Journal of Immunoassay and Immunochemistry

View full text Add to dashboard Cite

We performed method comparison for the tumor markers CA 15-3, CA 19-9, and CA 125 measured by luminescent oxygen channeling immunoassay technology on the Dimension Vista 1500 and by classic luminescence technology on the Immulite 2000 XPI. Within-day and total imprecision were determined according to Clinical and Laboratory Standards Institute (CLSI) guidelines using three serum pools at different clinically relevant levels. In addition, parallel measurements on both systems were performed in a total of 738 routine serum samples (133 CA 15-3, 395 CA 19-9, and 210 CA 125). Total imprecision of serum pools for CA 15-3 ranged between 4.6% and 5.9%, for CA 19-9 between 4.4% and 7.8%, and for CA 125 between 3.3% and 4.3%. Marker values determined within the measurement range of both systems correlated well with each other (R = 0.88 for CA 15-3, R = 0.93 for CA 19-9, and R = 0.96 for CA 125). Slopes between the Vista and the Immulite method were 0.96 for CA 125, 0.72 for CA 15-3, and 0.87 for CA 19-9, indicating lower values for CA 15-3 and CA 19-9 when measured by the Vista method. This was particularly obvious for CA 19-9 levels in the lower measuring range of <100 U/mL (R = 0.85; slope 0.73).

show abstract

CA 19–9, GICA (Gastrointestinal Cancer Antigen)

Cited by 9 publications

References 123 publications

Carbohydrate Antigen 19‐9 in Saliva

Carbohydrate Antigen 19‐9 in Saliva

Evaluation of imaging techniques and ca 19-9 in differential diagnosis of carcinoma and other focal lesions of pancreas

Method Comparison for Ca 15-3, Ca 19-9, and Ca 125 Determination Using the New Loci Technique of Dimension Vista 1500 and Immulite 2000 Xpi

Contact Info

Product

Resources

About